Effects of Myo-inositol on Type 1 Retinopathy of Prematurity Among Preterm Infants <28 Weeks' Gestational Age: A Randomized Clinical Trial.

Overview of attention for article published in JAMA: Journal of the American Medical Association, October 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
Above-average Attention Score compared to outputs of the same age and source (61st percentile)

Mentioned by

news: 6 news outlets
blogs: 2 blogs
twitter: 34 X users

facebook: 6 Facebook pages
googleplus: 2 Google+ users

Readers on

mendeley: 121 Mendeley

So far, Altmetric has seen 7 news stories from 6 outlets.

October 2018 Briefing - Ophthalmology

Drugs.com, 01 Nov 2018

Here are what the editors at HealthDay consider to be the most important developments in Ophthalmology for October 2018.

Myo-Inositol Does Not Reduce Retinopathy of Prematurity

Physician's Briefing, 24 Oct 2018

WEDNESDAY, Oct. 24, 2018 (HealthDay News) -- Treatment with myo -inositol for up to 10 weeks does not reduce the risk for type…

Myo-Inositol Does Not Reduce Retinopathy of Prematurity

Doctors Lounge, 24 Oct 2018

Treatment with myo-inositol for up to 10 weeks does not reduce the risk for type 1 retinopathy of prematurity or death versus…

Myo-Inositol Does Not Reduce Retinopathy of Prematurity

Drugs.com, 24 Oct 2018

WEDNESDAY, Oct. 24, 2018 -- Treatment with myo-inositol for up to 10 weeks does not reduce the risk for type 1 retinopathy of…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 3 additional news stories.